Vitaly Margulis, M.D.

Upon completion of a B.S. degree in biology and biochemistry with highest honors at the University of Texas, and honors medical degree at The University of Texas Southwestern Medical School, I was accepted into a highly competitive urology residency at the University of Texas Southwestern Medical Center in Dallas. During residency training, additional research time was focused on minimally invasive techniques to manage small renal masses, evaluation of a novel approach to perform nephron sparing surgery utilizing radiofrequency ablation, and utilization of tissue micro-array technology to evaluate biomarkers as predictors of bladder cancer outcome. Upon completion of rigorous clinical training in urology, I have entered and completed urologic oncology fellowship at the MD Anderson Cancer Center, where my research focus was on understanding the molecular biology of renal cell carcinogenesis and progression as a model for developing novel diagnostic and therapeutic strategies for this disease. Specifically, our group investigated the role of TGF-beta signal transduction in human renal cell carcinoma with goals of developing targeted therapies. Current scientific endeavors include identification of novel biomarkers in renal cell carcinoma, which could potentially allow for timely diagnosis, staging, prognostication and identification of candidates for adjuvant systemic therapies.

Medical School

UT Southwestern Medical School (2001)

Internship

UT Southwestern Medical Center (2002), General Surgery

Residency

UT Southwestern Medical Center (2006), Urology

Fellowship

UT MD Anderson Cancer Center (2009), Urologic Oncology

• Metastatic progression and resistance to targeted therapies
• Molecular biology involved in renal cell cancer tumorigenesis

Featured Publications

Magnetic Resonance Imaging - guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate

Costa D, Goldberg K, de Leon A, Lotan Y, XI Y, Aziz M, Frefeld Y, Margulis V, Raj G, Roehrborn CG, Hornberger B, Desai N, Bagrodia A, Francis F, Pedrosa I, Cadeddu J. 2019

Stereotactic radiation therapy of renal cancer inferior vena cava tumor thrombus

Freifeld Y, Margulis V, Woldu S, Timmerman R, Brugarolas J, Hannan R. 2019

Detection of invasive renal cell carcinoma with targeted molecular imaging

Margulis V, Hammers H, Sun X, Taneja S, Salzer J. 2019

Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy. Urologic Oncology: Seminars and Original Investigations

Freifeld Y, Xi Y, Passoni N, Woldu S, Hornberger B, Goldberg K, Bagrodia A, Raj G, Margulis V, Cadeddu J, Lotan Y, Francis F, Pedrosa I, Roehrborn CG, Costa D. 2018

Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.

Wang CJ, Christie A, Lin MH, Jung M, Weix D, Huelsmann L, Kuhn K, Meyer J, Desai N, Kim DWN, Pedrosa I, Margulis V, Cadeddu J, Sagalowsky A, Gahan J, Laine A, Xie XJ, Choy H, Brugarolas J, Timmerman R, Hannan R Int. J. Radiat. Oncol. Biol. Phys. 2017 May 98 1 91-100

A Multi-Institutional Comparison of Clinicopathological Characteristics and Oncologic Outcomes of Upper Tract Urothelial Carcinoma in China and the United States

Singla N, Fang D, Su X, Bao Z, Cao Z, Jafri SM, Xiong G, Zhang L, Hutchinson R, Sagalowsky AI, Lotan Y, Li X, Zhou L, Raman JD, Margulis V 2017

Impact of Hospital caseVolume on Testicular Cancer Outcomes and Practice Patterns

Woldu SL, Matulay JT, Clinton TN, Singla N, Krabbe LM, Hutchinson RC, Sagalowsky A, Lotan Y, Margulis V, Bagrodia A. 2017

Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses

Woldu Sl, Aydin AM, Rao AV, Hutchinson RC, Singla N, Clinton TN, Krabbe LM, Passoni NM, Raj GV, Miller DS, Amatruda JF, Sagalowsky A, Lotan Y, Arriaga Y, Margulis V, Bagrodia A. 2017

Oncology: Adrenal/Renal/Upper Tract/Bladder Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma

Krabbe LM, Heitzplatz B, Presuss S, Hutchinson RC, Woldu SL, Singla N, Boegemann M, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercg N, Haitel A, Rapoport LM, Glybochko PV, Roscigno M, Bolenz C, Bensaleh K, Sagalowsky AI, Shariat SF, Lotan Y, Xylinas E, Margulis V. 2017

Androgen receptor expression is associated with adverse pathological features in ureteral but not in pelvicalyceal urothelial carcinomas of the upper urinary tract.

Wirth GJ, Haitel A, Moschini M, Soria F, Klatte T, Hassler MR, Bensalah K, Briganti A, Karam JA, Lotan Y, Margulis V, Raman JD, Remzi M, Rioux-Leclercq N, Robinson BD, Rouprêt M, Wood CG, Shariat SF World J Urol 2016 Oct

• Merit Award
  American Society of Clinical Oncology (2008)
• National Institute of Health Clinical Research Scientist LRP Award
  NIH (2007)
• American Urological Association Foundation Research Scholar Award
  AFUD/AUA (2006)
• Ruth L. Kirschstein National Research Service Award
  University of Texas MD Anderson Cancer Center (2006)
• Alpha Omega Alpha
  UT Southwestern Medical School (2001)

• American Association for Cancer Research
• American College of Surgeons
• American Medical Association
• American Society of Clinical Oncology
• American Urological Association
• Dallas County Medical Society
• Endourologic Society
• Harris County Medical Society
• Society of Urologic Oncology
• Texas Medical Association